This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: I78.0 (hereditary hemorrhagic telangiectasia) | Special Copayment Reduction: V297 (rare disease) |
| B. Synonyms | Hereditary hemorrhagic telangiectasia | Rendu-Osler-Weber disease |
| C. Adult onset | Possibility of first onset in adulthood: high — recurrent epistaxis (nosebleeds) begins in childhood (mean age 12), but diagnosis is often made in the 30s–40s. Mucocutaneous telangiectatic lesions accumulate with increasing age and become prominent in adulthood, and serious complications due to pulmonary or cerebral arteriovenous malformations quite often first appear in adulthood. |
| 1. History | 1864 first description by Sutton → 1896 Rendu → 1901 Osler → 1907 systematized by Weber → 1994 ENG and ACVRL1 genes identified. |
| 2. Causes | Abnormal BMP9/TGF-β signaling → impaired vascular differentiation and stabilization → telangiectasia and arteriovenous malformations. Main genes: ENG, ACVRL1, SMAD4. |
| 3. Genetics | Autosomal dominant. HHT1 (ENG, 9q34), HHT2 (ACVRL1, 12q13), HHT3 (SMAD4, 18q21 — JP-HHT). Gene-negative in about 15–20%. |
| 4. General epidemiology | Prevalence 1/5,000–10,000. About 1 million worldwide. Diagnosis extremely low. High-prevalence regions exist, such as Denmark, French Quebec, and the island of Curaçao. |
| 5. Pathophysiology | Decreased ENG/ACVRL1 protein expression → reduced BMP9/ALK1 signaling → abnormal interaction between vascular endothelial cells and pericytes → formation of immature telangiectasia and AVMs. |
| 6. Symptoms | Recurrent epistaxis (95%), cutaneous and oral telangiectasia. Pulmonary AVM: dyspnea, paradoxical embolism (stroke, brain abscess). Cerebral AVM: headache, hemorrhage. GI bleeding. |
| 7. Signs | Telangiectatic lesions of the lips, tongue, and fingers; anemia. Pulmonary AVM: clubbing, cyanosis. Chest bruit. Curaçao criteria: epistaxis + skin lesions + family history + visceral AVM. |
| 8. Screening | For first-degree relatives with a family history: chest CT (pulmonary AVM), brain MRI/MRA (cerebral AVM), liver ultrasound. Genetic testing. Screening when 2 or more Curaçao criteria are met. |
| 9. Diagnosis | Curaçao clinical diagnostic criteria (3 for definite, 2 for suspected). Genetic testing (ENG, ACVRL1, SMAD4 panel). Pulmonary AVM: chest CT. Cerebral AVM: MRI/MRA/DSA. |
| 10. Treatment | Epistaxis: local hemostasis and nasal mucosal treatment. Pulmonary AVM: vascular embolization (coils, plugs). Cerebral AVM: embolization, surgery, radiation. Anemia: iron supplementation, transfusion. Bevacizumab (VEGF inhibitor, severe cases). |
| 11. Prognosis | With appropriate management, life expectancy similar to the general population. Untreated pulmonary AVM carries risks of paradoxical embolism, stroke, and brain abscess. Cerebral AVM hemorrhage can be fatal. |
| 12. Prevention | Family screening and early treatment of visceral AVMs (embolization). Careful use of antiplatelet agents and anticoagulants. Antibiotic prophylaxis before invasive procedures. Genetic counseling. |
| 13. References | Faughnan ME, et al. International HHT guidelines. Ann Intern Med. 2011 … and 9 other papers |
The historical description of hereditary hemorrhagic telangiectasia (HHT) dates back to the mid-19th century. In 1864, the British physician Henry Gawen Sutton first described a patient with recurrent epistaxis and cutaneous telangiectasia, and in 1876 Benjamin Guy of Britain and others reported additional similar cases. In 1896, Henri-Jules Louis Marie Rendu of France described in detail a patient with recurrent epistaxis and generalized telangiectasia, making clear that it was an independent disease distinct from hemophilia.
In 1901, the Canadian-born William Osler (then at Johns Hopkins Hospital) organized this syndrome more systematically. Osler described that telangiectatic lesions occur not only in the skin but also in the gastrointestinal mucosa, causing gastrointestinal bleeding, and emphasized the familial pattern of occurrence. In 1907, when Frederick Parkes Weber of Britain synthesized the features of this syndrome, it was named 'Rendu-Osler-Weber syndrome' after the three physicians, and the more descriptive name 'hereditary hemorrhagic telangiectasia (HHT)' subsequently also came into use.
In 1994, with advances in genetics, ENG (endoglin) (9q34), the causative gene of HHT1, was identified by McDonald et al., and in the same year ACVRL1 (ALK1) (12q13), the causative gene of HHT2, was identified by Vitali et al. Both genes were found to encode vascular endothelium-specific receptors involved in the TGF-β superfamily signaling pathway. Later, in 2004, SMAD4 variants were confirmed as the cause of HHT combined with hereditary polyposis (JP) (JP-HHT). Currently, HHT specialist centers worldwide and the international HHT Foundation play a central role in standardizing diagnostic criteria and supporting patients.
Hereditary hemorrhagic telangiectasia is a hereditary vascular malformation disease in which differentiation, stabilization, and maturation of vascular endothelial cells are impaired due to pathogenic variants in genes related to the BMP9/TGF-β superfamily signaling pathway.
There are three most important causative genes. ENG (endoglin): located on chromosome 9 (9q34.11), it encodes a coreceptor of the TGF-β receptor complex. ENG protein is highly expressed on the surface of vascular endothelial cells and regulates BMP9, TGF-β1, and TGF-β3 signaling. ENG variants cause the HHT1 subtype and show a strong association with pulmonary arteriovenous malformations (PAVMs) in particular. ACVRL1 (ALK1): located on chromosome 12 (12q13.13), it encodes ALK1 (activin receptor-like kinase 1), the direct receptor for BMP9/BMP10. ACVRL1 variants cause the HHT2 subtype, with a higher association with hepatic AVMs than HHT1. SMAD4: located on chromosome 18 (18q21.2), it encodes a transcription factor downstream of TGF-β/BMP9 signaling. SMAD4 variants cause JP-HHT (a combined syndrome of juvenile polyposis and HHT).
When expression of ENG or ACVRL1 protein is reduced by half due to haploinsufficiency, vascular endothelial cells cannot respond sufficiently to BMP9 signaling, and vessel wall formation proceeds abnormally. As a result, telangiectasia (abnormal dilation and fragility of small vessels) and arteriovenous malformations (AVMs, direct arteriovenous connections bypassing capillaries) are formed. There is also a hypothesis that, beyond haploinsufficiency, a 'two-hit model' is required for AVM formation.
Hereditary hemorrhagic telangiectasia is inherited in an autosomal dominant manner, with a 50% probability of the variant being transmitted from an affected parent to a child. It occurs equally in men and women.
The HHT-causing genes established to date are ENG (HHT1, about 40–50% of all cases), ACVRL1 (HHT2, about 40–50%), SMAD4 (JP-HHT, about 2%), and GDF2 (BMP9, HHT5, rare). In about 15–20% of all HHT patients, no pathogenic variants in these genes are identified, and they are classified as 'gene-negative HHT'. The search for additional causative genes is under way.
Clinical differences between ENG and ACVRL1 variants: in HHT1 (ENG variants), the prevalence of pulmonary AVMs is higher (about 30–50% vs about 10% in HHT2), and epistaxis tends to start at a younger age. In HHT2 (ACVRL1 variants), the prevalence of hepatic AVMs is higher (about 70% vs about 30% in HHT1), and clinical symptoms are generally milder. In JP-HHT (SMAD4 variants), gastrointestinal polyps (polyposis) accompany the HHT symptoms, increasing the risk of colon cancer. Colonoscopy screening is essential when a SMAD4 variant is confirmed.
Penetrance varies even within families, and expressivity also differs greatly. Among family members with the same variant, the spectrum is wide, ranging from asymptomatic cases to those with serious visceral AVM complications. Genetic testing is important for family screening and for determining who should undergo visceral AVM screening, and pulmonary AVM screening is recommended as a priority especially in ENG/SMAD4-positive individuals.
The prevalence of hereditary hemorrhagic telangiectasia is estimated at about 1 per 5,000–10,000 population. It is estimated that more than about 1 million people are affected worldwide, but the number of patients actually diagnosed is much smaller, and a considerable number are underdiagnosed.
HHT occurs in all races and ethnic groups, but there are regional variations. Regions with particularly high reported prevalence include Denmark (prevalence about 1/3,500), French Quebec (founder effect), and the island of Curaçao in the Dutch Caribbean (1/1,331), which is due to the founder effect (spreading over generations from a small group with the same variant). It occurs equally in men and women, and the onset and severity of clinical symptoms vary with age. Epistaxis begins in childhood, and symptoms of cutaneous telangiectasia and visceral AVMs become prominent mainly in adulthood.
In Korea, HHT is an ultra-rare disease without accurate prevalence statistics, but based on the global average, about 5,000–10,000 people are estimated to be affected. It is registered as eligible for Special Copayment Reduction (V297). Because HHT can cause serious complications such as iron deficiency anemia due to recurrent epistaxis, paradoxical embolism (stroke, brain abscess) due to pulmonary AVMs, and hemorrhage due to cerebral AVMs, early diagnosis and screening are very important.
The core of the pathophysiology of hereditary hemorrhagic telangiectasia is abnormal BMP9/ALK1/Endoglin signaling due to decreased expression of ENG or ACVRL1 protein. This signaling pathway is essential for maintaining the quiescent state of vascular endothelial cells, stabilizing the vessel wall, and recruiting pericytes.
Vascular endothelial abnormality: When BMP9 (GDF2) binds to ALK1 receptors on the surface of vascular endothelial cells, SMAD1/5/8 are phosphorylated, activating a transcriptional program that keeps endothelial cells in a 'quiescent' state. ENG is a coreceptor that amplifies BMP9/ALK1 signaling. When BMP9/ALK1 signaling is reduced by ENG or ACVRL1 haploinsufficiency, vascular endothelial cells enter an activated state, angiogenesis is excessively promoted, and pericyte recruitment is insufficient, making the vessel wall fragile.
Telangiectasia formation: Fragile capillaries dilate locally, forming telangiectasia. Telangiectasia occurs mainly in the skin (lips, tongue, fingers and toes, face), oral mucosa, nasal mucosa, and gastrointestinal mucosa. These lesions have very thin and fragile vessel walls, so bleeding occurs even with minor stimulation.
Arteriovenous malformation (AVM) formation: When the same abnormality occurs in larger vessels, arteriovenous malformations form in which arteries connect directly to veins without passing through capillaries. Pulmonary AVM (PAVM): arterial blood flows directly into the pulmonary veins without passing through the pulmonary capillaries, impairing the filtering function of the lungs. As a result, bacteria and clots enter the systemic circulation directly without passing through the lungs, causing paradoxical embolism (stroke, brain abscess). Cerebral AVM: when an AVM within the brain parenchyma ruptures, intracerebral hemorrhage or subarachnoid hemorrhage occurs. Hepatic AVM: intrahepatic arteriovenous shunting can cause high-output cardiac failure.
The clinical symptoms of hereditary hemorrhagic telangiectasia are divided into bleeding due to telangiectasia and complications of visceral AVMs.
Recurrent epistaxis: The most common symptom, occurring in about 95% of HHT patients. It is caused by rupture of telangiectasia in the nasal mucosa and starts at a mean age of 12. It begins with mild nosebleeds and gradually increases in frequency and amount. Long-term recurrent bleeding causes iron deficiency anemia, which is the most common cause of morbidity. The frequency, duration, and severity of epistaxis vary greatly between individuals.
Mucocutaneous telangiectasia: Punctate or linear erythematous lesions 1–3 mm in size appear on the lips, tongue, oral mucosa, fingertips, palms, and face. These lesions blanch when pressed with a glass, and their number increases toward adulthood.
Symptoms of pulmonary arteriovenous malformation (PAVM): PAVMs occur in about 30–50% of all HHT patients and are especially common in HHT1 (ENG variants). Symptoms: dyspnea on exertion, cyanosis (reduced oxygen saturation), streptococcal brain abscess (paradoxical embolism of oral bacteria such as Streptococcus intermedius), ischemic stroke (paradoxical embolism). Many PAVMs are asymptomatic, but the risks of infection and paradoxical embolism with invasive procedures are always present.
Symptoms of brain arteriovenous malformation (BAVM): Occurring in about 10–20% of HHT patients, they can present with headache, seizures, and neurological deficits. When an AVM ruptures, intracerebral or subarachnoid hemorrhage causes sudden death or serious neurological disability. Spinal cord AVMs can also occur.
Gastrointestinal bleeding (GI bleeding): Bleeding occurs from telangiectasia of the gastrointestinal mucosa, causing nausea and vomiting, bloody stool (blood), chronic occult blood, and severe iron deficiency anemia. It mainly occurs after the 50s and increases in frequency with age.
The physical signs of hereditary hemorrhagic telangiectasia reflect telangiectatic lesions, anemia, and the consequences of visceral AVMs.
Mucocutaneous telangiectatic lesions: Punctate, linear, or star-shaped red lesions 1–3 mm in size are observed on the lips, tongue, oral mucosa, nasal mucosa, fingertips (fingerprint area), palms, ears, and face. They blanch when pressed with a glass and turn red again when pressure is removed. This finding alone is an important clue for suspecting HHT.
Signs of anemia: Conjunctival pallor, skin pallor, and rapid heart rate suggest iron deficiency anemia. In severe anemia, cardiomegaly and a systolic murmur may appear. Spoon-shaped deformity of the nails (koilonychia) is a chronic sign of iron deficiency anemia.
Signs of pulmonary AVM: Digital clubbing, cyanosis, and polycythemia may appear. On auscultation, a bruit may be heard over the site of the pulmonary vascular malformation. Reduced oxygen saturation (SpO2 < 95%) is a clue to a significant PAVM.
Curaçao criteria: ① recurrent spontaneous epistaxis, ② mucocutaneous telangiectasia (multiple, at characteristic sites), ③ visceral lesions (gastrointestinal telangiectasia, pulmonary/hepatic/cerebral/spinal AVMs), ④ a first-degree relative with confirmed HHT. 3 or more criteria met: definite; 2: suspected; 1 or fewer: diagnosis not possible.
Systematic screening for hereditary hemorrhagic telangiectasia aims at early detection of asymptomatic visceral AVMs (especially pulmonary AVMs) to prevent fatal complications such as paradoxical embolism and hemorrhage.
Family screening: For first-degree relatives (parents, siblings, children) of patients with confirmed HHT, visceral AVM screening together with Curaçao criteria assessment is recommended. When a pathogenic variant has been identified in the family, targeted genetic testing is performed in first-degree relatives. If genetic testing is positive, visceral AVM screening proceeds; if negative, only clinical follow-up is done without additional imaging.
Pulmonary AVM screening: Pulmonary AVM screening is recommended in all patients with confirmed or suspected HHT. Non-contrast chest CT (thin-slice, 3 mm or less) is the first-line tool with high sensitivity for PAVMs. Contrast transthoracic echocardiography (bubble study, detection of bubbles in the left atrium after injection of saline bubbles) is useful for evaluating the functional right-to-left shunt of PAVMs. When a PAVM is found, detailed evaluation and treatment (coil embolization) are planned.
Cerebral AVM screening: At diagnosis in childhood or at first HHT diagnosis in adulthood, brain MRI/MRA is performed to evaluate cerebral AVMs. For cerebral AVMs found, size, location, and flow characteristics are evaluated to determine the need for treatment.
Hepatic AVM screening: Hepatic AVMs are evaluated by liver ultrasound (color Doppler) or abdominal CT. Extensive hepatic AVMs can lead to high-output cardiac failure, biliary ischemia, and portal hypertension. Asymptomatic hepatic AVMs are not treated but are followed up with observation.
Diagnosis of hereditary hemorrhagic telangiectasia is made by combining assessment of the Curaçao clinical criteria with genetic testing.
Curaçao clinical criteria: ① recurrent spontaneous epistaxis, ② mucocutaneous telangiectasia (multiple, at characteristic sites: lips, tongue, fingertips, oral cavity), ③ visceral lesions (gastrointestinal telangiectasia, pulmonary/hepatic/cerebral/spinal AVMs), ④ a first-degree relative with confirmed HHT. 3 or more of the 4 met = definite, 2 = suspected, 1 or fewer = diagnosis not possible. Definite diagnosis is possible with clinical criteria alone without genetic testing, but genetic testing facilitates subtype classification and family screening.
Genetic testing: HHT panel NGS including ENG, ACVRL1, and SMAD4 is recommended. With 2 clinical criteria (suspected diagnosis) and a positive gene test, definite diagnosis is possible. Even when gene-negative (about 15–20%), HHT management is applied if clinical criteria are met. If SMAD4-positive, the case is classified as JP-HHT and polyposis management is carried out in parallel.
Imaging diagnosis of visceral AVMs: Pulmonary AVM: non-contrast chest CT (reference standard), contrast echocardiography (functional assessment). Cerebral AVM: brain MRI + MRA, DSA when suspected. Hepatic AVM: abdominal ultrasound and CT, liver Doppler. Gastrointestinal tract: upper endoscopy and colonoscopy (direct confirmation of telangiectasia).
Evaluation of anemia and iron deficiency: Complete blood count (CBC), serum iron, ferritin, TIBC, reticulocyte count. Confirmation of iron deficiency anemia due to gastrointestinal bleeding and epistaxis.
Treatment of hereditary hemorrhagic telangiectasia consists of bleeding control, management of visceral AVMs, correction of anemia, and prevention of complications.
Treatment of epistaxis: For mild epistaxis, saline nasal drops, maintaining humidity, and nasal lubricants are used. For recurrent epistaxis, laser photocoagulation and electrocautery are used, but recurrence is common. Nasal closure (Young's procedure, closure of the nostrils) is used for severe epistaxis. Nasal septal hemostatic tampons (Merocel packing) are used for short-term hemostasis.
Treatment of pulmonary AVM: Pulmonary AVMs with a feeding artery diameter ≥3 mm are treated by embolization with coils or vascular plugs (Amplatzer vascular plug). Monitoring for re-enlargement is needed after embolization. Embolization markedly reduces the risk of paradoxical embolism and brain abscess.
Treatment of cerebral AVM: Depending on size, location, and bleeding risk, observation, radiosurgery (Gamma Knife, CyberKnife), vascular embolization, or surgical resection is chosen. The benefits and risks of treating unruptured cerebral AVMs are individualized and decided by a multidisciplinary team.
Treatment of iron deficiency anemia: Oral iron (ferrous sulfate, ferrous gluconate), intravenous iron injection (when oral iron is insufficient due to recurrent bleeding), transfusion (in severe anemia). Erythropoietin injection may be used adjunctively to improve anemia.
Bevacizumab (anti-VEGF): Clinical trials have shown intravenous bevacizumab to be effective in severe epistaxis, high-output cardiac failure due to hepatic AVMs, and gastrointestinal bleeding. It reduces abnormal angiogenesis by inhibiting VEGF. Thalidomide and pazopanib are also used in some cases.
Antibiotic prophylaxis (patients with AVMs): In patients with pulmonary AVMs, antibiotic prophylaxis is given before invasive procedures such as dental procedures, endoscopy, and endotracheal intubation to reduce the risk of brain abscess.
The prognosis of hereditary hemorrhagic telangiectasia depends greatly on the presence of visceral AVMs and whether they are treated. The life expectancy of appropriately diagnosed and managed patients may not differ greatly from that of the general population.
Pulmonary AVM complications and prognosis: If pulmonary AVMs are not treated with embolization, the cumulative risk of paradoxical embolism (ischemic stroke, transient ischemic attack) is about 1–2% per year, and the risk of brain abscess also increases. Stroke and brain abscess can be fatal or leave serious disability. After embolization this risk decreases markedly, but regular CT is needed to monitor for new PAVMs or re-enlargement of existing PAVMs.
Cerebral AVM complications and prognosis: When a cerebral AVM ruptures, the fatality rate and rate of permanent neurological disability are high. The annual bleeding risk of cerebral AVMs found before rupture is reported to be about 1–2%. Decisions on cerebral AVM treatment are made by comprehensively considering size, location, flow characteristics, and patient condition, and the benefit of treatment may be unclear for small deep AVMs.
Chronic effects of anemia: Chronic iron deficiency anemia due to long-term recurrent epistaxis reduces quality of life and affects cognitive function and exercise capacity. Active iron supplementation and treatment of epistaxis are central to anemia control.
Special prognosis of JP-HHT (SMAD4): In JP-HHT patients, gastrointestinal polyposis (small intestinal and colonic polyps) is present, so the risk of colon cancer and small intestinal cancer is higher than in ordinary HHT. Regular colonoscopy and small bowel imaging are needed.
Because hereditary hemorrhagic telangiectasia is a genetic disease, complete primary prevention is impossible, but complications can be prevented through early diagnosis and systematic screening.
Family screening and early treatment of visceral AVMs: Early diagnosis is made through genetic testing and clinical evaluation in first-degree relatives of confirmed patients, and pulmonary and cerebral AVMs are detected and treated (embolization) early to prevent paradoxical embolism and bleeding complications. In particular, pulmonary AVM embolization is very effective in preventing stroke and brain abscess.
Antibiotic prophylaxis before invasive procedures: In patients with pulmonary AVMs, prophylactic antibiotics (amoxicillin or clindamycin) for dental procedures, endoscopy, and endotracheal intubation prevent brain abscess caused by oral bacteria.
Careful use of antiplatelet agents and anticoagulants: In HHT patients, aspirin, NSAIDs, and anticoagulants can worsen epistaxis and gastrointestinal bleeding, so unnecessary use should be avoided, and when needed, an individualized decision is required that carefully weighs bleeding risk against the benefit of thrombosis prevention.
Genetic counseling: Because it is autosomal dominant and transmitted to 50% of children, genetic counseling is provided when a person with confirmed HHT plans to have children. Selection of unaffected embryos through preimplantation genetic testing (PGT) is possible in some families. Because pulmonary and cerebral AVMs may change during pregnancy, prenatal and postnatal monitoring is important.
Regular follow-up: After pulmonary AVM embolization, re-enlargement is monitored with chest CT every 1–3 years. Brain MRI is repeated every 3–5 years or when symptoms occur. Regular assessment of epistaxis frequency and anemia status. Regular colonoscopy in SMAD4 (JP-HHT) patients.
Faughnan ME, Palda VA, Garcia-Tsao G, et al. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet. 2011;48(2):73-87. DOI: 10.1136/jmg.2009.069013. PMID: 19553198.
Shovlin CL, Guttmacher AE, Buscarini E, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet. 2000;91(1):66-67. DOI: 10.1002/(SICI)1096-8628(20000306)91:1. PMID: 10751092.
Dupuis-Girod S, Ginon I, Saurin JC, et al. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA. 2012;307(9):948-955. DOI: 10.1001/jama.2012.250. PMID: 22396517.
Gossage JR, Kanj G. Pulmonary arteriovenous malformations: a state of the art review. Am J Respir Crit Care Med. 1998;158(2):643-661. DOI: 10.1164/ajrccm.158.2.9711008. PMID: 9700146.
Kjeldsen AD, Vase P, Green A. Hereditary haemorrhagic telangiectasia: a population-based study of prevalence and mortality in Danish patients. J Intern Med. 1999;245(1):31-39. DOI: 10.1046/j.1365-2796.1999.00398.x. PMID: 10095814.
McDonald J, Bayrak-Toydemir P, Pyeritz RE. Hereditary hemorrhagic telangiectasia: an overview of diagnosis, management, and pathogenesis. Genet Med. 2011;13(7):607-616. DOI: 10.1097/GIM.0b013e3182136d3f. PMID: 21546842.
Wooderchak-Donahue WL, McDonald J, O'Fallon B, et al. BMP9 mutations cause a vascular-anomaly syndrome with phenotypic overlap with hereditary hemorrhagic telangiectasia. Am J Hum Genet. 2013;93(3):530-537. DOI: 10.1016/j.ajhg.2013.07.004. PMID: 23972368.
van Gent MW, Velthuis S, Post MC, et al. Hereditary hemorrhagic telangiectasia: how accurate are the clinical criteria? Am J Med Genet A. 2013;161A(3):461-466. DOI: 10.1002/ajmg.a.35746. PMID: 23378011.
Shovlin CL. Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment. Blood Rev. 2010;24(6):203-219. DOI: 10.1016/j.blre.2010.07.001. PMID: 20870325.
Suppressa P, Liso A, Cirulli A, et al. An update on the genetics of hereditary hemorrhagic telangiectasia. Orphanet J Rare Dis. 2014;9:110. DOI: 10.1186/s13023-014-0110-7. PMID: 25060268.